Detalhe da pesquisa
1.
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
Haematologica
; 97(9): 1348-56, 2012 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-22419581
2.
Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
Cancer Res
; 65(21): 10041-9, 2005 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-16267030
3.
Clinical grade purification and expansion of natural killer cells.
Crit Rev Oncog
; 19(1-2): 121-32, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24941378
4.
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.
PLoS One
; 8(1): e54610, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-23372742
5.
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Mol Cancer Ther
; 8(9): 2616-24, 2009 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-19723891
6.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Blood
; 111(3): 1309-17, 2008 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-17947507
7.
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
Blood
; 105(10): 3939-44, 2005 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-15671442